All articles tagged with #multiple myeloma
GSK's blood cancer drug Blenrep received a narrower FDA approval than expected, leading to a more than 5% drop in GSK stock; despite showing some survival benefits in studies, concerns over ocular side effects and a panel's risk assessment limited its approval prospects.
The US FDA has approved GSK's Blenrep in combination with bortezomib and dexamethasone for treating relapsed/refractory multiple myeloma in patients who have received at least two prior therapies, based on positive results from the DREAMM-7 trial showing significant survival benefits. Blenrep is notable for its community accessibility and ongoing development in earlier treatment lines.
Bristol Myers Squibb announced that their Phase 3 EXCALIBER-RRMM study showed that combining iberdomide with standard therapies significantly improved minimal residual disease negativity rates in relapsed or refractory multiple myeloma patients, with the trial continuing to evaluate other endpoints.
Multiple myeloma is a rare blood cancer with subtle symptoms like fatigue, bone pain, and anemia, often leading to delayed diagnosis. Recognizing less obvious signs such as tingling, bubbles in urine, or persistent tiredness, especially in high-risk groups, is crucial for early detection and treatment.
A new FDA-approved treatment called Carvykti, a CAR T-cell therapy developed by Legend Biotech in New Jersey, offers a potential 'functional cure' for multiple myeloma, significantly extending remission periods and improving quality of life for patients like Carmen Phaneuf, who has managed to stay in remission for nearly three years after treatment.
A study shows that a single infusion of CAR-T therapy cilta-cel can lead to at least five years of remission in about one-third of patients with relapsed or refractory multiple myeloma, suggesting potential curative outcomes for some patients.
A clinical trial involving 97 patients with incurable multiple myeloma has shown promising results, with a third of participants living years without detectable cancer after immunotherapy, raising hope for a potential cure for this deadly blood cancer.
A new study suggests that a high-fiber, plant-based diet may help prevent the progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma, a common form of blood cancer. Conducted on 20 MGUS patients, the research found that dietary changes led to weight loss, improved insulin resistance, and a healthier gut microbiome, all contributing to a slowdown in disease progression. The findings, presented at the American Society of Hematology meeting, highlight the potential of nutrition in cancer prevention, with a larger study planned to further explore these results.
The FDA's Oncologic Drugs Advisory Committee voted 12 to 0 in favor of using minimal residual disease (MRD) as an accelerated approval endpoint in multiple myeloma clinical trials. This decision could potentially lead to earlier access to effective treatments for patients and the possibility of stopping therapy based on MRD. The use of MRD as an endpoint in different myeloma disease settings and the acceptability of time points for MRD assessment were also discussed during the meeting.
House Majority Leader Steve Scalise will be absent from Washington until February to undergo a stem cell transplant for his multiple myeloma treatment, impacting the already narrow Republican majority in the House. This comes at a critical time with looming government shutdown deadlines and the need for bipartisan support to pass legislation. Scalise, who has served as a leadership mentor to Speaker Mike Johnson after being unable to secure the speakership himself, will work remotely during his recovery. His medical challenges, including a previous critical injury from a shooting, highlight his resilience in the face of health issues.
Poseida Therapeutics presented positive early results from its Phase 1 trial of P-BCMA-ALLO1, an allogeneic CAR-T therapy, in relapsed/refractory multiple myeloma (RRMM) at the 65th American Society of Hematology (ASH) Annual Meeting. The therapy demonstrated an 82% overall response rate (ORR) and deep clinical responses in heavily pretreated patients, with no graft-vs-host disease (GvHD) or dose-limiting toxicities observed. The therapy also showed promising persistence and differentiation of CAR-T cells, supporting the potential of allogeneic T stem cell memory (TSCM)-rich CAR-T therapies. Poseida Therapeutics plans to continue developing P-BCMA-ALLO1 in partnership with Roche.
GSK has announced positive results from the DREAMM-7 phase III trial, showing that the combination of Blenrep (belantamab mafodotin) with bortezomib plus dexamethasone (BorDex) significantly extended progression-free survival (PFS) compared to the standard of care regimen of daratumumab plus BorDex in patients with relapsed or refractory multiple myeloma. The trial also showed a strong trend towards improved overall survival (OS). The safety profile of the combination was consistent with the known safety profile of the individual agents. Further data from the trial will be presented at a scientific meeting and shared with health authorities.
The FDA has delayed its decision on whether to approve Bristol Myers Squibb and 2seventy bio's CAR-T cell therapy for multiple myeloma in earlier lines of treatment. The regulator plans to hold a public meeting with outside experts to discuss the therapy, which was originally expected to receive a decision by December 16. Currently, the therapy is approved for multiple myeloma patients who have previously had four or more lines of treatment.
Christian LeBlanc, known for his role on The Young and the Restless, revealed that he has been battling Multiple myeloma, a form of blood cancer. He experienced symptoms such as weight loss and a tumor pressing on his optic nerve. After undergoing surgery and immunotherapy treatment, his cancer is now in remission, and he will be returning to the show for its Thanksgiving episode. LeBlanc, who came out as gay in 2021, has been married to his husband for 28 years.
The European Medicines Agency's Committee for Medicinal Products Human Use (CHMP) recommended seven new medicines for approval, including treatments for Duchenne muscular dystrophy, relapsed or refractory multiple myeloma, and hyperargininemia. The committee also granted extensions of therapeutic indications for eight medicines and initiated a review of the benefits and risks of a medicine used to treat primary biliary cholangitis.